Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This is a prospective, pilot, two-arm, randomized, multicenter study exploring the efficacy
and safety of osimertinib with or without savolitinib as first-line therapy in patients with
de novo MET positive, EGFR-mutant advanced NSCLC.